Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Maze Therapeutics (MAZE) Enterprise Value (2024 - 2025)

Maze Therapeutics has reported Enterprise Value over the past 2 years, most recently at -$341.9 million for Q4 2025.

  • Quarterly Enterprise Value fell 73.73% to -$341.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$341.9 million through Dec 2025, down 73.73% year-over-year, with the annual reading at -$341.9 million for FY2025, 73.73% down from the prior year.
  • Enterprise Value was -$341.9 million for Q4 2025 at Maze Therapeutics, up from -$383.9 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$30.0 million in Q1 2024 and troughed at -$383.9 million in Q3 2025.